Lexaria Bioscience Corp. (NASDAQ: LEXX) Grows Patent Portfolio to 43 Granted Patents Worldwide
Lexaria recently received two new patents granted in the U.S. in its patent families #21 and #24 The new patents complement the company’s efforts in investigating the capabilities of DehydraTECH-CBD to lower blood pressure in humans with hypertension and mitigate epileptic seizures in rodents The company relies on R&D to provide data that enables it to apply for patent protection, supports further investigations and discoveries, as well as increases its chances of potentially receiving FDA approvals According to CEO Chris Bunka, the company’s growing patent portfolio forms the foundation upon which the company forges commercial relationships Lexaria Bioscience (NASDAQ: LEXX),…
